Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc., a leading player in the pharmaceutical industry, is headquartered in Japan. Established in 1847, the company has made significant strides in the development of transdermal drug delivery systems, particularly through its popular product lines such as Salonpas, which offers pain relief patches. Hisamitsu operates extensively across Asia, Europe, and North America, solidifying its presence in the global market. Renowned for its innovative approach, Hisamitsu focuses on pain management and dermatological products, setting itself apart with unique formulations that enhance patient compliance. The company has achieved notable milestones, including the expansion of its product portfolio and strategic partnerships that bolster its market position. With a commitment to quality and innovation, Hisamitsu continues to be a trusted name in healthcare, dedicated to improving the lives of patients worldwide.
DitchCarbon Score
How does Hisamitsu Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hisamitsu Pharmaceutical Co's score of 23 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hisamitsu Pharmaceutical Co's reported carbon emissions
In 2022, Hisamitsu Pharmaceutical Co reported total carbon emissions of approximately 69,890,000 kg CO2e from Scope 1 and Scope 2, alongside significant contributions from Scope 3 emissions, which totalled about 51,179,000 kg CO2e. The breakdown of Scope 3 emissions includes capital goods (5,340,000 kg CO2e), business travel (473,000 kg CO2e), employee commute (255,000 kg CO2e), purchased goods and services (51,179,000 kg CO2e), waste generated in operations (2,095,000 kg CO2e), fuel and energy-related activities (2,167,000 kg CO2e), end-of-life treatment of sold products (25,651,000 kg CO2e), upstream transportation and distribution (2,161,000 kg CO2e), and downstream transportation and distribution (32,000 kg CO2e). In 2021, the company reported slightly lower emissions, with Scope 1 at 6,923,000 kg CO2e and Scope 2 at 15,862,000 kg CO2e, while Scope 3 emissions were approximately 48,284,000 kg CO2e. The 2020 figures were similar, with Scope 1 emissions at 6,986,000 kg CO2e and Scope 2 at 14,919,000 kg CO2e, while Scope 3 emissions reached about 53,479,000 kg CO2e. Despite these figures, Hisamitsu has not publicly committed to specific reduction targets or initiatives, indicating a potential area for future development in their climate strategy. The company operates within a global context where pharmaceutical firms are increasingly expected to address their carbon footprints and contribute to sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,986,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,919,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 100,228,000 | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hisamitsu Pharmaceutical Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
